- The document provides guidance for hepatology and liver transplant providers during the COVID-19 pandemic. It discusses what is known about how SARS-CoV-2 impacts the liver and patients with liver disease, and provides recommendations for evaluating COVID-19 patients with elevated liver enzymes. It also offers recommendations for managing stable outpatients with liver disease or HCC, including severely limiting non-essential visits, screening patients for COVID-19 symptoms, and using telemedicine when possible. The goal is to protect at-risk patients while continuing to provide care during the pandemic.
- The document provides clinical insights and recommendations for hepatology and liver transplant providers during the COVID-19 pandemic.
- It discusses the effects of SARS-CoV-2 on the liver, recommendations for evaluating patients with liver disease and elevated liver enzymes who have COVID-19, and considerations for managing outpatients and inpatients with liver disease during the pandemic.
- Key recommendations include limiting unnecessary in-person visits, screening patients for COVID-19 symptoms, continuing surveillance of HCC patients while delaying some tests and procedures, and developing policies for accepting organ offers and performing transplants during the pandemic.
This document discusses "long haulers" or patients experiencing persistent symptoms after acute COVID-19 infection. It provides epidemiological data showing a significant portion of patients reporting ongoing symptoms weeks or months after initial infection. Two case presentations are provided - one with a 73F experiencing dyspnea, fatigue and loss of taste months after hospitalization and found to have diastolic dysfunction. The second case is a 51F with intermittent cough and dyspnea for months with abnormal CT findings suggestive of organizing pneumonia. Management strategies are discussed for post-COVID headaches.
This document discusses sepsis in the context of COVID-19. It begins by defining sepsis and the related terms systemic inflammatory response syndrome, severe sepsis, and septic shock. It then discusses how COVID-19 can sometimes lead to sepsis through a dysregulated immune response and infection. The document outlines common clinical manifestations of sepsis in COVID-19 patients and risk factors. It recommends following the Surviving Sepsis Campaign guidelines for early detection and treatment of sepsis through measuring lactate levels, administering antibiotics and fluids, and other interventions within 3-6 hours of recognition.
Nutrition in COVID-19 a Guideline and Practice Based ApproachSubha Deep
This presentation summarizes my effort of discussing the ASPEN and ESPEN guidelines in a Seminar for proper nutrition in all types of COVID19 patients. I am sharing this over the internet because It will allow healthcare providers to provide information for the provision of better nutrition and care among patients. This PPT is made open to all and all the details are taken from are from the mentioned respective studies and authors. As a scientific scholar and doctor, I am sharing the data mentioning their due references. All articles mentioned are open access and you may reach out and read them at length for any issues. Please do not use data without reference from these articles for copyright issues.
CME Lecture on "COVID-19 Presentation and Diagnosis"
Presented at the Scientific Seminar of Philippine American Medical Association in Chicago on March 6th, 2021.
This document summarizes treatment guidelines for COVID-19 based on disease severity and stage:
- Monoclonal antibodies like Sotrovimab and Bebtelovimab can reduce hospitalization when given early for mild-moderate cases. Antiviral pills Paxlovid and Molnupiravir may also be options.
- For hospitalized patients, remdesivir, corticosteroids like dexamethasone, and IL-6 inhibitors like tocilizumab are recommended. Baricitinib may also help reduce mortality. Remdesivir works best early in hospitalization while corticosteroids are preferred later for patients with ARDS.
- Guidelines discuss optimal dosing of cort
This document summarizes guidelines for the management of hepatitis C virus (HCV) infection from the European Association for the Study of the Liver (EASL). Key points include:
- HCV infects an estimated 160 million people worldwide and is a major cause of chronic liver disease. New direct-acting antiviral drugs have improved treatment outcomes.
- The guidelines provide recommendations on diagnosing, assessing, and treating HCV infection. They address issues like determining liver disease severity, HCV genotyping, treatment goals and endpoints, and contraindications to therapy.
- For HCV genotype 1, the current standard of care is combination therapy with pegylated interferon, ribavirin, and one of two protease
- The document provides clinical insights and recommendations for hepatology and liver transplant providers during the COVID-19 pandemic.
- It discusses the effects of SARS-CoV-2 on the liver, recommendations for evaluating patients with liver disease and elevated liver enzymes who have COVID-19, and considerations for managing outpatients and inpatients with liver disease during the pandemic.
- Key recommendations include limiting unnecessary in-person visits, screening patients for COVID-19 symptoms, continuing surveillance of HCC patients while delaying some tests and procedures, and developing policies for accepting organ offers and performing transplants during the pandemic.
This document discusses "long haulers" or patients experiencing persistent symptoms after acute COVID-19 infection. It provides epidemiological data showing a significant portion of patients reporting ongoing symptoms weeks or months after initial infection. Two case presentations are provided - one with a 73F experiencing dyspnea, fatigue and loss of taste months after hospitalization and found to have diastolic dysfunction. The second case is a 51F with intermittent cough and dyspnea for months with abnormal CT findings suggestive of organizing pneumonia. Management strategies are discussed for post-COVID headaches.
This document discusses sepsis in the context of COVID-19. It begins by defining sepsis and the related terms systemic inflammatory response syndrome, severe sepsis, and septic shock. It then discusses how COVID-19 can sometimes lead to sepsis through a dysregulated immune response and infection. The document outlines common clinical manifestations of sepsis in COVID-19 patients and risk factors. It recommends following the Surviving Sepsis Campaign guidelines for early detection and treatment of sepsis through measuring lactate levels, administering antibiotics and fluids, and other interventions within 3-6 hours of recognition.
Nutrition in COVID-19 a Guideline and Practice Based ApproachSubha Deep
This presentation summarizes my effort of discussing the ASPEN and ESPEN guidelines in a Seminar for proper nutrition in all types of COVID19 patients. I am sharing this over the internet because It will allow healthcare providers to provide information for the provision of better nutrition and care among patients. This PPT is made open to all and all the details are taken from are from the mentioned respective studies and authors. As a scientific scholar and doctor, I am sharing the data mentioning their due references. All articles mentioned are open access and you may reach out and read them at length for any issues. Please do not use data without reference from these articles for copyright issues.
CME Lecture on "COVID-19 Presentation and Diagnosis"
Presented at the Scientific Seminar of Philippine American Medical Association in Chicago on March 6th, 2021.
This document summarizes treatment guidelines for COVID-19 based on disease severity and stage:
- Monoclonal antibodies like Sotrovimab and Bebtelovimab can reduce hospitalization when given early for mild-moderate cases. Antiviral pills Paxlovid and Molnupiravir may also be options.
- For hospitalized patients, remdesivir, corticosteroids like dexamethasone, and IL-6 inhibitors like tocilizumab are recommended. Baricitinib may also help reduce mortality. Remdesivir works best early in hospitalization while corticosteroids are preferred later for patients with ARDS.
- Guidelines discuss optimal dosing of cort
This document summarizes guidelines for the management of hepatitis C virus (HCV) infection from the European Association for the Study of the Liver (EASL). Key points include:
- HCV infects an estimated 160 million people worldwide and is a major cause of chronic liver disease. New direct-acting antiviral drugs have improved treatment outcomes.
- The guidelines provide recommendations on diagnosing, assessing, and treating HCV infection. They address issues like determining liver disease severity, HCV genotyping, treatment goals and endpoints, and contraindications to therapy.
- For HCV genotype 1, the current standard of care is combination therapy with pegylated interferon, ribavirin, and one of two protease
This study evaluated the safety and efficacy of pegylated interferon alpha-2a (PEG-IFN) monotherapy in 78 hepatitis C virus (HCV) positive hemodialysis patients. An early viral response was seen in 61.5% of patients at 12 weeks. However, only 19.2% had undetectable HCV RNA levels at end of treatment. A sustained viral response was achieved in 14.1% of the initial population. Adherence was poor, with 32% unable to complete the 48-week treatment due to adverse effects. Adverse events were common, occurring in 83% of patients. The incidence of serious adverse events was high at 0.19 per patient-year. The study
This document provides a summary of the methods used to develop recommendations for testing, managing, and treating hepatitis C virus (HCV) infection from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). An expert panel reviews evidence from various sources to develop recommendations that are rated based on strength. The guidance aims to provide up-to-date advice for healthcare providers as new therapies become available.
- Hepatitis C is a contagious liver disease caused by the Hepatitis C virus. It can range from mild to severe and lifelong.
- It is commonly spread through blood-to-blood contact, especially from intravenous drug use. Other potential sources of transmission include sexual contact, transfusions, and from mother to child.
- Diagnosis involves blood tests to detect HCV antibodies and the virus. Additional tests like liver function tests and biopsy may also be used. There is no vaccine but risk of transmission can be reduced through safe practices.
The document outlines the World Health Organization's guidelines for COVID-19 care pathways. It discusses establishing care pathways at the local, regional, and national levels to suppress transmission, provide optimized patient care, and minimize the pandemic's impact on health systems. The COVID-19 care pathway involves confirming diagnoses, treating patients, assessing their progress, deciding on discharge, and post-discharge follow-up. The goals are to improve patient care, maximize resource use, and support clinical processes.
Hepatitis b virus in haemodialysis patients. mostafa abdel salam mohamed, muhdarsh 1980
This document discusses vaccination and occult hepatitis in dialysis patients. It provides an overview of vaccination, including how vaccines work and milestones in immunization history. It then discusses challenges to vaccination response in dialysis patients due to immune suppression. Rates of hepatitis B surface antigen positivity vary globally among dialysis populations, from under 1% to over 16%. Occult hepatitis B can occur when hepatitis B virus DNA is present despite surface antigen being undetectable. Liver biopsy is the definitive way to assess liver disease activity before antiviral treatment or transplantation.
Best Practices in the Management of HCV. 2015hivlifeinfo
In this downloadable slideset, Andrew J. Muir, MD, reviews the evidence informing current guidance and best practices on treating patients with hepatitis C.
Format: Microsoft PowerPoint (.ppt)
File size: 1.97 MB
Efficacy and safety of Sulfad tablets in supporting patientswith viral
hepatitis:Aprospective,double-blind,randomized, placebo-controlled,
phase III clinical trial
Noncommunicable diseases (NCDs) such as heart disease, cancer, respiratory diseases, and diabetes account for over 70% of deaths globally each year. Risk factors for NCDs, like cardiovascular disease and diabetes, can also lead to more severe cases of COVID-19. The pandemic has made it difficult for patients with NCDs to access routine medical care. Telemedicine has been promoted in India to help patients with chronic conditions receive care during lockdowns when in-person services are limited. Continued monitoring is needed to assess the long-term health impacts of the pandemic on patients with NCDs.
Presynmptoms SARS-Cov-2 Infection and Transmission in Skilled Nursing FacilityValentina Corona
- A Covid-19 outbreak occurred at a skilled nursing facility in King County, Washington.
- Two point-prevalence surveys were conducted, and 57 of 89 residents (64%) tested positive for SARS-CoV-2.
- Many residents who tested positive were asymptomatic at the time of testing, and most developed symptoms within a week. Asymptomatic and pre-symptomatic residents likely contributed to transmission within the facility.
- The document provides guidelines for diagnosing and treating acute myocardial infarction (AMI) and protecting cardiologists during the COVID-19 outbreak.
- It outlines five general principles for AMI treatment, including near local treatment and safe protection of patients. It also provides flowcharts for diagnosing and managing STEMI and NSTEMI patients.
- Advice is given for outpatient management, including screening for fever and respiratory symptoms. Designated hospitals and isolation are recommended for suspected or confirmed COVID-19 patients needing intervention.
- Detailed prevention and control procedures are described for consultation of patients in fever clinics and emergency interventional procedures. Personal protective equipment and designated pathways are emphasized to protect cardiologists.
Hepatitis c infection, causes, treatment, and preventionNada Sami
1) Hepatitis C virus (HCV) was identified in 1989 and is a leading cause of liver disease. Egypt has the largest HCV epidemic in the world with a prevalence of 14.7% based on antibody testing.
2) HCV is a small enveloped RNA virus that is classified into 6 major genotypes. Genotypes 1 and 4 typically require longer treatment than genotypes 2, 3, 5 and 6.
3) HCV infection may be acute or chronic. About 60-70% of infections become chronic and 20% of chronic carriers may develop cirrhosis or liver cancer over time if left untreated.
This document summarizes guidelines for evaluating and treating a 73-year-old man with symptoms of possible COVID-19 (fever, cough, worsening shortness of breath). It recommends that patients with mild symptoms typically recover at home, while those with moderate or severe symptoms may require hospitalization for supportive care. There are currently no proven drug therapies for COVID-19, so referral to clinical trials is important. Infection control focuses on protective equipment for healthcare workers, social distancing, and testing.
This document provides guidance from the British Thoracic Society (BTS) on respiratory follow-up of patients diagnosed with COVID-19 pneumonia. It outlines two follow-up algorithms - one for more severe patients requiring ICU care, and one for mild-moderate cases not requiring ICU care.
For severe cases, it recommends an early virtual or in-person review at 4-6 weeks to assess symptoms, rehabilitation needs, etc. At 12 weeks, all severe cases should have an in-person review including chest x-ray to check for resolution.
For mild-moderate cases, it recommends a virtual chest x-ray review at 12 weeks. If clear, patients will be discharged with advice to seek care if new
The document discusses the prevention of hepatitis B and C infections in hemodialysis patients, noting that bloodborne virus transmission was recognized as a hazard in renal units in the 1960s. It recommends screening and surveillance of patients and staff, segregation and immunization of infected patients, implementation of universal precautions including hand hygiene and personal protective equipment, and disinfection of equipment to prevent the spread of hepatitis B and C viruses in hemodialysis settings.
This document summarizes information from Dr. Tahseen J. Siddiqui on COVID-19. It discusses the three known coronaviruses that cause SARS, MERS, and COVID-19. It emphasizes that mitigation through strict social isolation is the best current strategy to slow transmission rates and prevent healthcare systems from being overwhelmed. The risks of personal infection are low but systemic risks are high if many require critical care simultaneously. Early action through testing, contact tracing, and quarantines have helped countries like Taiwan better control the spread.
Mass general covid 19 treatment guideline july012020Adiel Ojeda
This document provides guidance for clinicians at Massachusetts General Hospital (MGH) on the treatment of COVID-19. It summarizes recommended diagnostic testing and risk stratification for hospitalized patients. It also provides guidance on therapeutic considerations, including anti-infectives, cardiovascular medications, antithrombotics, and COVID-19 specific treatments such as remdesivir. The document is regularly updated as new data emerges on the management of COVID-19.
Restart fertility in Covid19: Indian Perspective and International GuidanceShivani Sachdev
Here are the key precautions and sanitization procedures that should be followed during scans to minimize risk of COVID-19 transmission:
- Limit the number of people present in the scanning room to only the patient and sonographer. No additional family members/friends.
- Both the patient and sonographer should wear a surgical mask.
- The scanning room and equipment including ultrasound probe, console, keyboards etc. should be sanitized after each patient using a disinfectant wipe or 70% alcohol. Pay special attention to frequently touched surfaces.
- Disposable probe covers should be used for each patient and disposed off properly after use.
- Thorough hand hygiene should be performed by the sonographer before and
This study evaluated the safety and efficacy of pegylated interferon alpha-2a (PEG-IFN) monotherapy in 78 hepatitis C virus (HCV) positive hemodialysis patients. An early viral response was seen in 61.5% of patients at 12 weeks. However, only 19.2% had undetectable HCV RNA levels at end of treatment. A sustained viral response was achieved in 14.1% of the initial population. Adherence was poor, with 32% unable to complete the 48-week treatment due to adverse effects. Adverse events were common, occurring in 83% of patients. The incidence of serious adverse events was high at 0.19 per patient-year. The study
This document provides a summary of the methods used to develop recommendations for testing, managing, and treating hepatitis C virus (HCV) infection from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA). An expert panel reviews evidence from various sources to develop recommendations that are rated based on strength. The guidance aims to provide up-to-date advice for healthcare providers as new therapies become available.
- Hepatitis C is a contagious liver disease caused by the Hepatitis C virus. It can range from mild to severe and lifelong.
- It is commonly spread through blood-to-blood contact, especially from intravenous drug use. Other potential sources of transmission include sexual contact, transfusions, and from mother to child.
- Diagnosis involves blood tests to detect HCV antibodies and the virus. Additional tests like liver function tests and biopsy may also be used. There is no vaccine but risk of transmission can be reduced through safe practices.
The document outlines the World Health Organization's guidelines for COVID-19 care pathways. It discusses establishing care pathways at the local, regional, and national levels to suppress transmission, provide optimized patient care, and minimize the pandemic's impact on health systems. The COVID-19 care pathway involves confirming diagnoses, treating patients, assessing their progress, deciding on discharge, and post-discharge follow-up. The goals are to improve patient care, maximize resource use, and support clinical processes.
Hepatitis b virus in haemodialysis patients. mostafa abdel salam mohamed, muhdarsh 1980
This document discusses vaccination and occult hepatitis in dialysis patients. It provides an overview of vaccination, including how vaccines work and milestones in immunization history. It then discusses challenges to vaccination response in dialysis patients due to immune suppression. Rates of hepatitis B surface antigen positivity vary globally among dialysis populations, from under 1% to over 16%. Occult hepatitis B can occur when hepatitis B virus DNA is present despite surface antigen being undetectable. Liver biopsy is the definitive way to assess liver disease activity before antiviral treatment or transplantation.
Best Practices in the Management of HCV. 2015hivlifeinfo
In this downloadable slideset, Andrew J. Muir, MD, reviews the evidence informing current guidance and best practices on treating patients with hepatitis C.
Format: Microsoft PowerPoint (.ppt)
File size: 1.97 MB
Efficacy and safety of Sulfad tablets in supporting patientswith viral
hepatitis:Aprospective,double-blind,randomized, placebo-controlled,
phase III clinical trial
Noncommunicable diseases (NCDs) such as heart disease, cancer, respiratory diseases, and diabetes account for over 70% of deaths globally each year. Risk factors for NCDs, like cardiovascular disease and diabetes, can also lead to more severe cases of COVID-19. The pandemic has made it difficult for patients with NCDs to access routine medical care. Telemedicine has been promoted in India to help patients with chronic conditions receive care during lockdowns when in-person services are limited. Continued monitoring is needed to assess the long-term health impacts of the pandemic on patients with NCDs.
Presynmptoms SARS-Cov-2 Infection and Transmission in Skilled Nursing FacilityValentina Corona
- A Covid-19 outbreak occurred at a skilled nursing facility in King County, Washington.
- Two point-prevalence surveys were conducted, and 57 of 89 residents (64%) tested positive for SARS-CoV-2.
- Many residents who tested positive were asymptomatic at the time of testing, and most developed symptoms within a week. Asymptomatic and pre-symptomatic residents likely contributed to transmission within the facility.
- The document provides guidelines for diagnosing and treating acute myocardial infarction (AMI) and protecting cardiologists during the COVID-19 outbreak.
- It outlines five general principles for AMI treatment, including near local treatment and safe protection of patients. It also provides flowcharts for diagnosing and managing STEMI and NSTEMI patients.
- Advice is given for outpatient management, including screening for fever and respiratory symptoms. Designated hospitals and isolation are recommended for suspected or confirmed COVID-19 patients needing intervention.
- Detailed prevention and control procedures are described for consultation of patients in fever clinics and emergency interventional procedures. Personal protective equipment and designated pathways are emphasized to protect cardiologists.
Hepatitis c infection, causes, treatment, and preventionNada Sami
1) Hepatitis C virus (HCV) was identified in 1989 and is a leading cause of liver disease. Egypt has the largest HCV epidemic in the world with a prevalence of 14.7% based on antibody testing.
2) HCV is a small enveloped RNA virus that is classified into 6 major genotypes. Genotypes 1 and 4 typically require longer treatment than genotypes 2, 3, 5 and 6.
3) HCV infection may be acute or chronic. About 60-70% of infections become chronic and 20% of chronic carriers may develop cirrhosis or liver cancer over time if left untreated.
This document summarizes guidelines for evaluating and treating a 73-year-old man with symptoms of possible COVID-19 (fever, cough, worsening shortness of breath). It recommends that patients with mild symptoms typically recover at home, while those with moderate or severe symptoms may require hospitalization for supportive care. There are currently no proven drug therapies for COVID-19, so referral to clinical trials is important. Infection control focuses on protective equipment for healthcare workers, social distancing, and testing.
This document provides guidance from the British Thoracic Society (BTS) on respiratory follow-up of patients diagnosed with COVID-19 pneumonia. It outlines two follow-up algorithms - one for more severe patients requiring ICU care, and one for mild-moderate cases not requiring ICU care.
For severe cases, it recommends an early virtual or in-person review at 4-6 weeks to assess symptoms, rehabilitation needs, etc. At 12 weeks, all severe cases should have an in-person review including chest x-ray to check for resolution.
For mild-moderate cases, it recommends a virtual chest x-ray review at 12 weeks. If clear, patients will be discharged with advice to seek care if new
The document discusses the prevention of hepatitis B and C infections in hemodialysis patients, noting that bloodborne virus transmission was recognized as a hazard in renal units in the 1960s. It recommends screening and surveillance of patients and staff, segregation and immunization of infected patients, implementation of universal precautions including hand hygiene and personal protective equipment, and disinfection of equipment to prevent the spread of hepatitis B and C viruses in hemodialysis settings.
This document summarizes information from Dr. Tahseen J. Siddiqui on COVID-19. It discusses the three known coronaviruses that cause SARS, MERS, and COVID-19. It emphasizes that mitigation through strict social isolation is the best current strategy to slow transmission rates and prevent healthcare systems from being overwhelmed. The risks of personal infection are low but systemic risks are high if many require critical care simultaneously. Early action through testing, contact tracing, and quarantines have helped countries like Taiwan better control the spread.
Mass general covid 19 treatment guideline july012020Adiel Ojeda
This document provides guidance for clinicians at Massachusetts General Hospital (MGH) on the treatment of COVID-19. It summarizes recommended diagnostic testing and risk stratification for hospitalized patients. It also provides guidance on therapeutic considerations, including anti-infectives, cardiovascular medications, antithrombotics, and COVID-19 specific treatments such as remdesivir. The document is regularly updated as new data emerges on the management of COVID-19.
Restart fertility in Covid19: Indian Perspective and International GuidanceShivani Sachdev
Here are the key precautions and sanitization procedures that should be followed during scans to minimize risk of COVID-19 transmission:
- Limit the number of people present in the scanning room to only the patient and sonographer. No additional family members/friends.
- Both the patient and sonographer should wear a surgical mask.
- The scanning room and equipment including ultrasound probe, console, keyboards etc. should be sanitized after each patient using a disinfectant wipe or 70% alcohol. Pay special attention to frequently touched surfaces.
- Disposable probe covers should be used for each patient and disposed off properly after use.
- Thorough hand hygiene should be performed by the sonographer before and
The document provides information about COVID-19 and the NSW Health response. It defines SARS-CoV-2, the virus that causes COVID-19, and details the timeline of the outbreak worldwide and in Australia. It describes NSW Health's response, which includes establishing clinical councils, providing advice to healthcare workers, developing diagnostic tests, managing cases through infection control and public health measures, and regular public updates. It provides guidance on case definitions, testing criteria, and infection prevention and control strategies to prevent transmission, including the use of personal protective equipment and isolation for suspected or confirmed cases.
Mgh COVID-19 Treatment Guidance March 17, 2020Ken Yale
This document was developed by members of the ID division at MGH in conjunction with pharmacy, radiology, and other medicine divisions to provide guidance to frontline clinicians caring for patients with COVID-19. This document covers potential off-label and/or experimental use of medications and immunosuppression management for transplant patients as well as a suggested laboratory work up. It does NOT cover recommendations for infection control, PPE, management of hypoxemia or other complications in patients with COVID-19. This is a living document that will be updated in real time as more data emerge.
This document provides guidance from Massachusetts General Hospital on potential treatment options for COVID-19, including both approved and experimental therapies. It recommends supportive care for mild cases but considers investigational antivirals like remdesivir for moderate or severe cases. It also outlines monitoring and treatment guidance for special populations, potential side effects of therapies, and criteria for considering treatments targeting cytokine release syndrome. The guidance is intended to be updated frequently as new data emerges on COVID-19 treatment.
This document provides guidance from Massachusetts General Hospital on potential treatment options for COVID-19, including both approved and experimental therapies. It recommends supportive care for mild cases but considers investigational antivirals like remdesivir for moderate or severe cases. It also outlines monitoring and treatment guidance for special populations, potential side effects of therapies, and criteria for considering treatments targeting cytokine release syndrome. The guidance is intended to be updated frequently as new data emerges on COVID-19 treatment.
Evidance based managment of COVID-19 patientsSaren Azer
This document provides guidance on evidence-based management of the COVID-19 outbreak from Dr. Saren Azer, an immunologist and critical care physician. It summarizes recommendations from WHO on screening, infection control, treatment of mild and severe cases, and specimen collection. It emphasizes the importance of infection control and preparing for a potential humanitarian crisis from this pandemic.
This document discusses COVID-19 in immunocompromised patients. It notes that while immunocompromised patients are at higher risk of severe COVID-19 due to an impaired immune response, the suppression of inflammation may also be protective. The effects of various immunocompromising conditions like HIV, cancer, transplant recipients, and primary immunodeficiencies on COVID-19 outcomes are reviewed. Management strategies like antiviral therapy and immunoglobulin replacement are also discussed. More research is still needed to understand how immunocompromise impacts COVID-19 severity.
Paul E. Sax, MD prepared useful Practice Aids pertaining to COVID-19 for this CME/MOC/CNE/CPE activity titled "Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical Guidance for Healthcare Professionals on the Front Lines of Patient Care." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at https://bit.ly/3gBvfOw. CME/MOC/CNE/CPE credit will be available until July 23, 2021.
International webinar on chemotherapy in impact of covid 19Mallika Vhora
The document discusses the impact of COVID-19 on cancer patients undergoing chemotherapy. It begins with an introduction on COVID-19 and describes how cancer patients are at higher risk from the virus due to immunosuppression from chemotherapy or their cancer. Delaying or interrupting chemotherapy can allow cancer to progress or relapse and reduce quality of life for palliative patients. Sources note chemotherapy patients require testing for COVID-19 before treatment due to risks. While short delays may be managed, prolonged interruptions over 3 months could reduce therapeutic benefits. The document examines challenges Indian cancer patients face in receiving care during the pandemic.
Slide deck cancer care during covid 19 pandemicmadurai
This document provides guidance for cancer care during the COVID-19 pandemic from several medical organizations. It discusses that cancer patients may be more susceptible to COVID-19 and have poorer outcomes. It recommends postponing non-urgent visits and elective surgeries, continuing critical cancer treatments when possible, and increasing telehealth to reduce infections. Safety measures like PPE and social distancing are crucial to protect staff and patients. Treatment should be individualized based on risk factors.
This document provides interim guidance for clinicians on managing patients with suspected or confirmed COVID-19. It outlines recommendations for screening, triage, infection prevention and control measures, specimen collection, and treatment of mild, severe, and critical COVID-19 cases. Key recommendations include screening all patients for COVID-19 at first contact, implementing droplet precautions like masks and patient isolation, and optimizing supportive care including oxygen therapy and monitoring for complications like ARDS, sepsis and septic shock. The guidance is meant to strengthen clinical management and provide best practices based on evidence from COVID-19 and other respiratory virus outbreaks.
Update on anticoagulant in Covid 19 and Safety ProtocolDimasRioBalti
The document provides updated guidance on anticoagulation for COVID-19 patients from the Philippine Society of Vascular Medicine. It recommends:
1. Initiating prophylactic anticoagulation for hospitalized COVID-19 patients with moderate to critical illness, and those with mild illness and high risk of VTE.
2. Using intermediate doses for critically ill ICU patients. Therapeutic doses are suggested for confirmed VTE or high clinical suspicion.
3. Assessing VTE and bleeding risk prior to discharge to determine if post-discharge thromboprophylaxis is needed based on risk scores and D-dimer level.
4. Continuing to monitor for new evidence as understanding of COVID-
1. The document discusses SARS-CoV-2, the virus that causes COVID-19, including its transmission, clinical manifestations, risk factors, investigations, and management guidelines.
2. Key points include that SARS-CoV-2 is transmitted via droplets or contact and may cause asymptomatic to critical illness. Common symptoms include fever, cough and shortness of breath.
3. Older adults and those with pre-existing medical conditions are at higher risk for severe illness. Diagnosis is confirmed via RT-PCR testing of respiratory samples, while chest imaging may show pneumonia.
COVID-19 is caused by SARS-CoV-2 virus and has developed into a worldwide pandemic. The virus can affect the cardiovascular system by directly infecting heart cells or causing inflammation. For those with congenital heart disease, risk of serious illness from COVID-19 is higher for those over 70, with complex heart conditions, lung disease, or other health problems. While little is known about effects on those with CHD, children may be less severely affected than adults. Treatment focuses on symptoms, and most cases can be managed at home with self-care.
This document provides guidance for clinicians on the clinical management of patients with severe acute respiratory infection (SARI) when COVID-19 is suspected. It recommends screening all patients for suspected COVID-19 at the first point of contact. It defines mild, severe and critical COVID-19 illness and recommends immediate implementation of infection prevention and control measures. The document is organized to guide clinicians through patient care from screening to management of complications.
2015 ESC Guidelines on Infective Endocarditis ppt. by Dr Abhishek Rathore MDdrabhishekbabbu
The document summarizes guidelines for the management of infective endocarditis (IE). It recommends an endocarditis team approach in a reference center for complicated IE cases. It emphasizes the importance of early diagnosis, antibiotic therapy, and consideration of early surgery. It also discusses new recommendations for specific IE situations, antibiotic prophylaxis, surgical management, and the roles of imaging and multidisciplinary care in IE management.
Provides information on diagnosis and management of HIV-2 in adults, including an overview of HIV-2 and clinical recommendations and key points regarding diagnosis and treatment of HIV-2, monitoring antiretroviral therapy (ART), pregnancy, and pre- and post-exposure prophylaxis (PrEP and PEP).
Find more information at https://www.hivguidelines.org/hiv-testing-acute-infection/hiv-2/
Sponsored by the New York State Department of Health (NYSDOH) AIDS Institute (AI) and the HIV Clinical Guidelines Program
The American Gastroenterological Association (AGA) has published new guidance on gastrointestinal (GI) symptoms of COVID-19. The guidance notes that while GI symptoms like diarrhea, nausea and abdominal pain are present in some COVID-19 patients, they are less common than initially estimated, affecting around 7-8% of patients. However, COVID-19 can in some cases present initially with GI symptoms alone before developing respiratory symptoms. The guidance advises gastroenterologists to monitor patients for additional COVID-19 symptoms if new GI issues emerge and consider testing if respiratory symptoms develop. It also states that liver abnormalities in COVID-19 patients are usually due to secondary effects rather than direct virus-induced injury.
This document summarizes international data on gastrointestinal (GI) and liver manifestations of COVID-19 from a systematic review and meta-analysis of 47 studies including 10,890 patients. The pooled prevalence of GI symptoms was 7.7% for diarrhea, 7.8% for nausea/vomiting, and 2.7% for abdominal pain. Studies outside of China reported higher prevalences, with diarrhea in 18.3% of patients. Liver enzyme abnormalities occurred in 15.0% of patients for AST and ALT. Based on these findings, the document provides best practice statements for the consultative management of GI and liver issues in patients with COVID-19.
People with asthma should continue their prescribed inhaled medications to control their condition. During asthma attacks, oral corticosteroids should be taken if instructed and severe asthma may require long-term oral steroids combined with other treatments. Nebulizers should be avoided due to risk of spreading COVID-19, instead using pressurized inhalers with spacers. Patients should continue routine asthma medications and nasal steroids for allergies while limiting medical appointments and tests.
The document provides an update from the American Society for Reproductive Medicine (ASRM) Coronavirus/COVID-19 Task Force on their recommendations for patient management and clinical care during the pandemic. It affirms their previous recommendations from March 17th to suspend new treatment cycles and considers cancelling embryo transfers. It also clarifies that infertility treatment is a disease, though some treatments may be postponed. The task force emphasizes maximizing telehealth, ensuring safety of in-person care, and supporting the broader pandemic response effort.
The document discusses gastrointestinal manifestations and potential fecal-oral transmission of COVID-19. It notes that while respiratory symptoms are most common, diarrhea and other gastrointestinal symptoms have been reported. Mounting evidence suggests the virus can infect cells in the digestive system and be present in stool. This raises the possibility of fecal-oral transmission, making the digestive system an alternative infection route. More research is still needed to understand the virus's effects on the gastrointestinal system and liver.
Patients with inflammatory bowel disease should continue their usual IBD therapies including scheduled infusions during the COVID-19 pandemic. Having IBD does not increase the risk of SARS-CoV-2 infection or developing COVID-19. For IBD patients who develop COVID-19, they should stop thiopurines, methotrexate, tofacitinib, and biological therapies and only restart after complete resolution of COVID-19 symptoms, though they should speak to their healthcare team first before stopping any medications.
Investigators from China published two papers describing the impact of the coronavirus on the digestive tract. Key findings included that a significant portion of patients experienced gastrointestinal symptoms like diarrhea and nausea before respiratory symptoms, viral RNA was detectable in patient stool, and viral gastrointestinal infection and potential fecal-oral transmission can persist even after respiratory tract clearance, suggesting prevention of fecal-oral transmission is important to control virus spread.
This study provides evidence that SARS-CoV-2, the virus that causes COVID-19, can infect and replicate in human gastrointestinal tissues and may be transmitted via the fecal-oral route. The study found that SARS-CoV-2 RNA was present in the stool of over 50% of hospitalized COVID-19 patients and that some patients continued testing positive in stool even after respiratory samples became negative. Examination of gastrointestinal tissues from one patient found the SARS-CoV-2 receptor ACE2 expressed abundantly in gastrointestinal epithelial cells and detected viral proteins in these cells, indicating they were infected. This suggests the gastrointestinal tract may be an additional transmission route and that stool testing and precautions may be needed after respiratory clearance of the
This document is an infographic image file from the American Gastroenterological Association discussing the coronavirus and inflammatory bowel disease. The image file is titled "Coronavirus IBD CPU digital graphics_Infographic_Twitter.jpg" and is 1024x512 pixels in size located at an Amazon S3 URL. It is part of a project labeled "COM20-015".
This document provides guidance on managing patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. It recommends first determining if a patient's symptoms are due to active IBD or COVID-19 infection by testing for SARS-CoV-2 virus and considering disease activity markers. For COVID-19 negative patients, IBD treatment should continue based on disease severity. If infected, IBD treatment is adjusted based on COVID-19 severity and includes continuing certain medications, holding others, and resuming treatments after recovery. The focus is treating both diseases while minimizing risks.
This document provides recommendations for everyday health and preparedness steps in clinics in response to the COVID-19 outbreak. It recommends screening patients prior to arrival by assessing the need for the visit and asking about symptoms. It also recommends minimizing non-essential visits, implementing social distancing measures, frequent cleaning and disinfection of surfaces, and educating patients and staff on COVID-19 symptoms and protocols. Recommendations are provided on personal protective equipment, between-patient cleaning, end of day cleaning, hand hygiene, limiting items in waiting areas, and informing staff not to work if symptomatic.
- The document provides tips for dementia caregivers during the COVID-19 pandemic, including monitoring for increased confusion as an illness symptom, practicing good hand hygiene, planning alternatives if regular care is disrupted, having backup care plans if the primary caregiver gets sick, and checking on visitation policies and communication options for those in assisted living.
The document provides recommendations for migraine sufferers during the COVID-19 pandemic, including having an adequate supply of migraine medications, considering alternatives to in-person doctor visits, being mindful of routines and diet to reduce triggers, practicing social distancing and good hand hygiene, and finding alternative methods of social interaction while social distancing.
EASY TUTORIAL OF HOW TO USE CAPCUT BY: FEBLESS HERNANEFebless Hernane
CapCut is an easy-to-use video editing app perfect for beginners. To start, download and open CapCut on your phone. Tap "New Project" and select the videos or photos you want to edit. You can trim clips by dragging the edges, add text by tapping "Text," and include music by selecting "Audio." Enhance your video with filters and effects from the "Effects" menu. When you're happy with your video, tap the export button to save and share it. CapCut makes video editing simple and fun for everyone!
Maximize Your Content with Beautiful Assets : Content & Asset for Landing Page pmgdscunsri
Figma is a cloud-based design tool widely used by designers for prototyping, UI/UX design, and real-time collaboration. With features such as precision pen tools, grid system, and reusable components, Figma makes it easy for teams to work together on design projects. Its flexibility and accessibility make Figma a top choice in the digital age.
Explore the essential graphic design tools and software that can elevate your creative projects. Discover industry favorites and innovative solutions for stunning design results.
Revolutionizing the Digital Landscape: Web Development Companies in Indiaamrsoftec1
Discover unparalleled creativity and technical prowess with India's leading web development companies. From custom solutions to e-commerce platforms, harness the expertise of skilled developers at competitive prices. Transform your digital presence, enhance the user experience, and propel your business to new heights with innovative solutions tailored to your needs, all from the heart of India's tech industry.
ARENA - Young adults in the workplace (Knight Moves).pdfKnight Moves
Presentations of Bavo Raeymaekers (Project lead youth unemployment at the City of Antwerp), Suzan Martens (Service designer at Knight Moves) and Adriaan De Keersmaeker (Community manager at Talk to C)
during the 'Arena • Young adults in the workplace' conference hosted by Knight Moves.
Architectural and constructions management experience since 2003 including 18 years located in UAE.
Coordinate and oversee all technical activities relating to architectural and construction projects,
including directing the design team, reviewing drafts and computer models, and approving design
changes.
Organize and typically develop, and review building plans, ensuring that a project meets all safety and
environmental standards.
Prepare feasibility studies, construction contracts, and tender documents with specifications and
tender analyses.
Consulting with clients, work on formulating equipment and labor cost estimates, ensuring a project
meets environmental, safety, structural, zoning, and aesthetic standards.
Monitoring the progress of a project to assess whether or not it is in compliance with building plans
and project deadlines.
Attention to detail, exceptional time management, and strong problem-solving and communication
skills are required for this role.
Fonts play a crucial role in both User Interface (UI) and User Experience (UX) design. They affect readability, accessibility, aesthetics, and overall user perception.
Technoblade The Legacy of a Minecraft Legend.Techno Merch
Technoblade, born Alex on June 1, 1999, was a legendary Minecraft YouTuber known for his sharp wit and exceptional PvP skills. Starting his channel in 2013, he gained nearly 11 million subscribers. His private battle with metastatic sarcoma ended in June 2022, but his enduring legacy continues to inspire millions.